drugset
drugset / Trial / NCT00034177

Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium

NCT00034177 ↗

Phase 2 Completed 27 enrolled Achieve Life Sciences
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients locally advanced, metastatic, or recurrent transitional cell carcinoma of the urothelium.

Timeline

Start
2002-04
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 80 mg/m2 —
Subject Paclitaxel Small molecule 100 mg/m2 —
Subject Paclitaxel Small molecule 120 mg/m2 —

Indications

urothelial carcinoma